IPO ARMY (@IPOARMY) header
IPO ARMY (@IPOARMY) profile picture

IPOs, SPACs, BIO Stocks. NOT financial advice! For all IPO and SPAC updates, please join my Patreon page: https://xitter.cf/t.co/A3InlVoTsY

USA
Joined August 2021
Who’s ready for the @SpaceX IPO? SpaceX is aiming to file its IPO prospectus as soon as early next week, per multiple reports. Listing possible in June. • Potential Raise: Over $75 billion — could be the largest IPO in history! • Target Valuation: ~$1.5–1.75 trillion.
1
1
5
602
$ALGS back on the move 6M share float /$80M MC, anchored by best-/first-in-class CHB backbone therapy advancing through mid-Phase 2b, alongside a high-value MASH program with recent GLP-1 + ALG combination data demonstrating weight loss, potential out-licensing deal in 1H ’26.
4
1
6
2,696
One year ago $TERN was $5.50. It just hit $45.00 (+720%). That’s biotech — the gems are out there if you’re early and patient.
I officially added $TERN to my bio portfolio. I believe they are highly undervalued with multiple drugs in thier pipeline. TERN-601 (GLP-1), TERN-501 (THR-β agonist) and TERN-701 (treating CML) with an expected update im early December.
7
2,098
$ALGS one to watch again. This time last year ran from $7 to $46, in a month and a half. After that it was insanely oversold to ~$4 a share, now at $9. Another example of an undervalued biotech, amazing opportunity. Up 35.5% this week, smart money is starting to roll back in.
3
1
1
8
1,905
$SPRB $124 bid. “It’s the float, stupid”.
1
540
$3B valuation for MASH P3. What’s the combined valuation for $ALGS with best/first-in-class MASH + CHB? CEO says MASH deal expected early 2026. Who makes the next move — @merck @pfizer @JNJNews @GileadSciences ?
$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.
1
1,376
$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.
1
2
1,999
$ALGS 👀
I'll be the first to say it—Baker Brothers led the $105M private placement announced today for $ALGS. “There are always those who know how to play the game.” Baker Brothers have a proven track record of identifying biotech winners early, backing companies that went on 1/3
5
2,440
The One Allergy Stock That Might Outgrow $AQST and $SPRY Combined: patreon.com/posts/biotech-ge…
I’ve been doing a ton of DD on a biotech stock that’s still flying under the radar. While most companies in the allergy space focus on symptomatic relief—through autoinjectors, sublingual films, or intranasal sprays ( $SPRY, $AQST) 1/4
1
1
4,144
I’ve been doing a ton of DD on a biotech stock that’s still flying under the radar. While most companies in the allergy space focus on symptomatic relief—through autoinjectors, sublingual films, or intranasal sprays ( $SPRY, $AQST) 1/4
2
1
1
3,261
It’s also the only publicly traded player this close to potentially changing the standard of care. With a regulatory decision possible as early as 2026, the timeline is closer than most realize. 3/4
1
1
764
Oh, and btw—Baker Bros just took a 20% stake in the company. Not investment advice. But some of the most compelling innovations are often overlooked—until they’re not. 4/4
1
687